Journal of Diagnostics Concepts & Practice >

2021 , Vol. 20 >Issue 03: 265 - 370

DOI: https://doi.org/10.16150/j.1671-2870.2021.03.007

Original articles

Expression of HIF-1α and its relationship with prognosis in papillary renal cell carcinoma

Expand
  • a. Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    b. Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-04-27

  Online published: 2022-06-28

Fold

Abstract

Objects: To investigate the expression of hypoxia inducible factor-1ɑ（HIF-1ɑ） in papillary renal cell carcinoma (PRCC) and its relationship with microvessel density so as to explore the correlation of HIF-1ɑ expression with prognosis in PRCC patients. Methods: Immunohistochemistry was used to detect the expression of HIF-1ɑ in PRCC and para-carcinoma tissue and the relationship between expression of HIF-1ɑ and MVD was analyzed. Survival data were eva-luated with Kaplan-Meier and Log-rank method, and the significant factors were further analyzed with Cox model multivariate regression analysis. Results: The positive expression rate of HIF-1ɑ was 42.17% (35/83), and the positive expression rates in typeⅠand type II PRCC were 32.65% and 55.88%, respectively. The MVD in typeⅡPRCC was higher than that in typeⅠPRCC (40.74 /HP vs 25.63/HP), and HIF-1ɑ expression was positively correlated with MVD (γ=0.65). The 5-year survival rate of 83 PRCC patients was 89.16% (74/83), and of the 13 death cases, 10 cases were type Ⅱ PRCC. The Kaplan-Meier survival curve analysis showed that typeⅠPRCC had a better prognosis than typeⅡ. Univariate analysis revealed that Fuhrman grade Ⅲ-Ⅳ, occurrence of distant metastasis and HIF-1ɑ expression were risk factors for prognosis in PRCC patients (P<0.05). Multivariate analysis showed that HIF-1ɑ expression, Fuhrman grade, subtype of PRCC and distant metastasis were risk factors for poor prognosis. Conclusions: HIF-1ɑ expression is higher in typeⅡPRCC than in typeⅠPRCC, and HIF-1ɑ expression is a risk factor for poor prognosis in PRCC patients.

Key words： Papillary renal cell carcinoma; Hypoxia inducible factor-1α; Microvessel density; Prognosis

Cite this article

RUI Wenbin, XU Da, ZHU Yu, WU Yuxuan, WANG Haofei, WANG Chenghe, YUAN Fei . Expression of HIF-1α and its relationship with prognosis in papillary renal cell carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2021 , 20(03) : 265 -370 . DOI: 10.16150/j.1671-2870.2021.03.007

References

[1] Faria M, Shepherd P, Pan Y, et al. The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling[J]. Oncotarget, 2018, 9(91):36273-36288.
[2] Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene[J]. Cancer Cell, 2003, 3(4):347-361.
[3] Zhang K, Xu P, Sowers JL, et al. Proteome analysis of hypoxic glioblastoma cells reveals sequential metabolic adaptation of one-carbon metabolic pathways[J]. Mol Cell Proteomics, 2017, 16(11):1906-1921.
[4] Triner D, Shah YM. Hypoxia-inducible factors: a central link between inflammation and cancer[J]. J Clin Invest, 2016, 126(10):3689-3698.
[5] Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases[J]. Cancer Res, 1999, 59(22):5830-5835.
[6] Weidner N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147(1):9-19.
[7] Gudas LJ, Fu L, Minton DR, et al. The role of HIF1α in renal cell carcinoma tumorigenesis[J]. J Mol Med (Berl), 2014, 92(8):825-836.
[8] Chintala S, Najrana T, Toth K, et al. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of hypoxia-inducible factor 1 and 2 alpha by sele-nium in clear cell renal cell carcinoma leads to tumor growth inhibition[J]. BMC Cancer, 2012, 12:293.
[9] Medina Villaamil V, Aparicio Gallego G, Santamarina Caínzos I, et al. Searching for Hif1-α interacting proteins in renal cell carcinoma[J]. Clin Transl Oncol, 2012, 14(9):698-708.
[10] Lidgren A, Hedberg Y, Grankvist K, et al. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray[J]. Eur Urol, 2006, 50(6):1272-1277.
[11] Saleeb RM, Plant P, Tawedrous E, et al. Integrated phenotypic/genotypic analysis of papillary renal cell carcinoma subtypes: identification of prognostic markers, cancer-related pathways, and implications for therapy[J]. Eur Urol Focus, 2018, 4(5):740-748.
[12] Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma[J]. Cancer Cell, 2011, 20(4):511-523.
[13] 董樑, 黄吉炜, 奚倩雯, 等. 乳头状肾细胞癌的临床病理特征和预后分析[J]. 中华泌尿外科杂志, 2015, 36(3):183-187.
[14] 高明珠, 王进有, 张海梁, 等. 乳头状肾癌的临床病理特征及其预后因素[J]. 中国癌症杂志, 2014, 24(4):299-303.
[15] Chen Y, Shuch B, Kluger H, et al. High WHO/ISUP Grade and unfavorable architecture, rather than typing of papillary renal cell carcinoma, may be associated with worse prognosis[J]. Am J Surg Pathol, 2020, 44(5):582-593.
[16] Ren W, Gao X, Zhang X, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management[J]. Clin Transl Oncol, 2020, 22(5):725-733.
[17] Feng J, Xie G, Zhan Y, et al. Elevated HSP90 associates with expression of HIF-1α and p-AKT and is predictive of poor prognosis in nasopharyngeal carcinoma[J]. Histopathology, 2019, 75(2):202-212.
[18] Baba Y, Nosho K, Shima K, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colo-rectal cancers[J]. Am J Pathol, 2010, 176(5):2292-2301.
[19] Swartz JE, Pothen AJ, van Kempen PM, et al. Poor prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinomas that overexpress hypoxia inducible factor-1α[J]. Head Neck, 2016, 38(9):1338-1346.
[20] Shamis SAK, McMillan DC, Edwards J. The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 159:103231.
[21] Minardi D, Lucarini G, Santoni M, et al. Survival in patients with clear cell renal cell carcinoma is predicted by HIF-1alpha expression[J]. Anticancer Res, 2015, 35(1):433-438.
[22] Ebru T, Fulya OP, Hakan A, et al. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma[J]. Int Braz J Urol, 2017, 43(3):440-454.
[23] Fan Y, Li H, Ma X, et al. Prognostic significance of hypoxia-inducible factor expression in renal cell carcinoma: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine(Baltimore), 2015, 94(38):e1646.
[24] Deng J, Li L, Xia H, et al. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis[J]. Medicine (Baltimore), 2019, 98(27):e16309.
[25] Stenman M, Staehler M, Szabados B, et al. Metastatic papillary renal cell carcinoma in the era of targeted the-rapy - a retrospective study from three European academic centres[J]. Acta Oncol, 2019, 58(3):306-312.
[26] Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase Ⅱ study (SUPAP) by the French Genitourinary Group (GETUG)[J]. Ann Oncol, 2015, 26(6):1123-1128.
Options
Outlines

/

〈 〉